Patent CN113801233A discloses coupling Boc-modified semaglutide propeptide with Fmoc compound (such as Fmoc-His-Aib or Fmoc-His-Aib-Glu), removing Boc-linked tertiary butyl protected side chain, removing Fmoc, and removing tertiary butyl to obtain semaglutide, which has many steps, and requires frequent deprotection (3 times of deprotection) to cause racemization of some amino acids, especially racemization of terminal His and introduction of other impurities with incomplete Fmoc removal, thereby causing great difficulty in subsequent purification
The US Food and Drug Administration has also approved certain GLP-1 medications to treat obesity
Wouldnt we as a collective sporting world look back on this conversation and think about it differently
The protein works in different mechanisms, the main one is increasing the secretion of insulin, which reduces blood sugar
Page MJ et al
A new drug, compound 6, does just that